Return to homepagePandemic Pact

Differences in Prognosis between hypertensive patients using ACEI and BRAS and using other classes of antihypertensive drugs infected with SARS-cov-2

  • Funded by Decanato de Pesquisa e Inovação - Universidade de Brasilia (DPI)
  • Total publications:5 publications

Grant number: 1019945

Grant search

Key facts

  • Disease

    COVID-19

  • Known Financial Commitments (USD)

    $27,867.48

  • Funder

    Decanato de Pesquisa e Inovação - Universidade de Brasilia (DPI)

  • Principal Investigator

    Unspecified Márcia Renata Mortari

  • Research Location

    Brazil

  • Lead Research Institution

    N/A

  • Research Priority Alignment

    N/A

  • Research Category

    Clinical characterisation and management

  • Research Subcategory

    Prognostic factors for disease severity

  • Special Interest Tags

    N/A

  • Study Type

    Clinical

  • Clinical Trial Details

    Not applicable

  • Broad Policy Alignment

    Pending

  • Age Group

    Adults (18 and older)

  • Vulnerable Population

    Unspecified

  • Occupations of Interest

    Unspecified

Abstract

On January 28, 2020, the number of confirmed cases of SARS-Cov-2 in the world exceeded 600,000 and the number of deaths exceeded the 27,000,000 mark. The lethality rate of this virus in patients without any comorbidity is only 1.4% while it reaches 8.4% in hypertensive patients, according to research carried out by the WHO in China, a reality that urges research on the action of the virus in patients with systemic arterial hypertension. In addition, patients with cardiovascular diseases are the main population in a state of severe infection, comprising 23.4% of those infected with the need for a mechanical respirator. In addition, studies in progress around the world point to a possible association between the poor prognosis in hypertensive patients contaminated by COVID-19 and the previous use of ACEI and BRAS.

Publicationslinked via Europe PMC

Last Updated:an hour ago

View all publications at Europe PMC

Contact exposure to environmentally relevant pesticide residues in beeswax may affect honey bees in a laboratory setting.

A Meta-Omics Approach Using eDNA and eRNA for the Assessment of Biotic Communities Associated With Royal Jelly Produced by the Western Honey Bee (Apis mellifera L.).

Development of a multiplex real-time quantitative reverse-transcription polymerase chain reaction for the detection of four bee viruses.

Evaluating the seasonal efficacy of commonly used chemical treatments on Varroa destructor (Mesostigmata: Varroidae) population resurgence in honey bee colonies.

Oxalic acid application method and treatment intervals for reduction of Varroa destructor (Mesostigmata: Varroidae) populations in Apis mellifera (Hymenoptera: Apidae) colonies.